SCHEMBL2365284

SCHEMBL2365284

O=c1cnc2cccc(Cl)c2[nH]1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.50
CA9 Q16790 1/20 0.50
PARP1 P09874 2/20 0.42
KDM4E B2RXH2 1/20 0.41
HCAR1 Q9BXC0 2/20 0.41
DAO P14920 3/20 0.39
NOS1 P29475 1/20 0.39
MAPKAPK2 P49137 1/20 0.39
RPS6KA3 P51812 1/20 0.39
CSNK2A1 P68400 1/20 0.39
PLK3 Q9H4B4 1/20 0.39
GUSB P08236 1/20 0.38
ADORA3 P0DMS8 1/20 0.38
ADORA1 P30542 1/20 0.38
AKR1B1 P15121 1/20 0.38
PDE3B Q13370 1/20 0.37
PDE3A Q14432 1/20 0.37
AHR P35869 1/20 0.37
CLK1 P49759 1/20 0.37
CDK9 P50750 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5318244 0.78 KDM4E (0.42) PARP1KDM4EHCAR1DAOMAPKAPK2
SCHEMBL30297078 0.78 CA12 (0.50) CA12CA9PARP1KDM4EHCAR1
SCHEMBL1043395 0.78 MAPKAPK2 (0.39) PARP1KDM4EDAOMAPKAPK2RPS6KA3
SCHEMBL30297088 0.78 CA12 (0.50) CA12CA9PARP1KDM4EHCAR1
SCHEMBL2800776 0.78 CA12 (0.50) CA12CA9KDM4EHCAR1DAO
SCHEMBL17844981 0.74 RXFP1 (0.44) CA12CA9KDM4EHCAR1DAO
SCHEMBL9039429 0.74 ALDH1A1 (0.43) KDM4EHCAR1MAPKAPK2RPS6KA3CSNK2A1
SCHEMBL22654726 0.74 UPP1 (0.40) KDM4EMAPKAPK2RPS6KA3CSNK2A1PLK3
SCHEMBL15935194 0.74 KIF11 (0.40) PARP1KDM4EHCAR1MAPKAPK2RPS6KA3
SCHEMBL1041178 0.74 NQO2 (0.50) KDM4EHCAR1DAOPDE3BPDE3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3604288-B1 REGIOSELECTIVE ONE-STEP PROCESS FOR SYNTHESIZING 2-HYDROXYQUINOXALINE DEV CT BIOTECHNOLOGY (TW) 2024-04-10 EP disclosed
CN-110483421-B Preparation method of quinoxalinone derivative 沈阳师范大学 2022-06-10 CN disclosed
CN-110790713-B Regioselective one-step process for the synthesis of 2-hydroxyquinoxaline 财团法人生物技术开发中心 2021-03-05 CN disclosed
CN-110790713-A Regioselective one-step process for the synthesis of 2-hydroxyquinoxaline 财团法人生物技术开发中心 2020-02-14 CN disclosed
EP-3604288-A1 REGIOSELECTIVE ONE-STEP PROCESS FOR SYNTHESIZING 2-HYDROXYQUINOXALINE Development Center for Biotechnology (TW) 2020-02-05 EP disclosed
EP-3604288-A1 REGIOSELECTIVE ONE-STEP PROCESS FOR SYNTHESIZING 2-HYDROXYQUINOXALINE Development Center for Biotechnology (TW) 2020-02-05 EP disclosed
EP-2352725-A1 QUINOXALINE-BASED LXR MODULATORS Wyeth LLC (US) 2011-08-10 EP disclosed
WO-2010054229-A1 QUINOXALINE-BASED LXR MODULATORS WYETH LLC (US) 2010-05-14 WO disclosed
US-20100120778-A1 QUINOXALINE-BASED LXR MODULATORS WYETH (US) 2010-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120778-A1 QUINOXALINE-BASED LXR MODULATORS NR1H2, NR1H3, NR1H4 CA12 4778/4885CA9 3174/4885PARP1 4063/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.